Schizophrenia and smoking

Journal of Clinical Psychiatry

Volumn 73, Issue 6, 2012, Pages

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLOZAPINE; CYTOCHROME P450 1A2; OLANZAPINE; RISPERIDONE;

ADULT; CASE REPORT; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INDUCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOLLOW UP; HUMAN; HYPERSALIVATION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; SHORT SURVEY; SMOKING; SMOKING CESSATION; SOMNOLENCE;

EID: 84863543133     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12f07732     Document Type: Short Survey

References (18)

1. Aubin HJ, Rollema H, Svensson TH, et al. Smoking, quitting, and psychiatric disease: a review. Neurosci Biobehav Rev. 2012;36(1):271-284. doi:10.1016/j.neubiorev.201.06.07 PubMed
2. Urichuk L, Prior TI, Dursun S, et al. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008;9(5):410-418. doi:10.2174/ 1389208784746373 PubMed (Pubitemid 352025195)
3. Chetty M, Murray M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab. 2007;8(4):307-313. doi:10.2174/13892078065469 PubMed (Pubitemid 46780060)
4. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64(18):1917-1921. doi:10.2146/ajhp060414 PubMed (Pubitemid 47462906)
5. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother. 2010;44(4):727-732. doi:10.1345/aph.1M398 PubMed
6. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62(12):1049-1053. doi:10.107/s028-06-0209-9 PubMed (Pubitemid 44786497)
7. Derenne JL, Baldessarini RJ. Clozapine toxicity associated with smoking cessation: case report. Am J Ther. 2005;12(5):469-471. doi:10.1097/01.mjt.01462. 59764.d PubMed (Pubitemid 41445145)
8. Ross S, Williams D. Bupropion: risks and benefits. Expert Opin Drug Saf. 2005;4(6):995-1003. doi:10.1517/1474038.4.6.95 PubMed (Pubitemid 41671598)
9. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc). 2003;39(7):551-557. doi:10.1358/dot.203.39.7.7945 PubMed (Pubitemid 37187418)
10. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76(2):178-184. doi:10.1016/j.clpt.204.04.03 PubMed (Pubitemid 39013407)
11. Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2010;196(5):346-353. doi:10.192/bjp.bp.109.06019 PubMed
12. Kotlyar M, Brauer LH, Tracy TS, et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol. 2005;25(3):226-229. doi:10.1097/01.jcp. 0162805.46453.e3 PubMed (Pubitemid 40685785)
13. Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol. 1999;55(8):599-604. doi:10.107/s028050679 PubMed (Pubitemid 29489207)
14. Mihara K, Suzuki A, Kondo T, et al. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Ther Drug Monit. 2000;22(3):245-249. doi:10.1097/07691-2060-02 PubMed (Pubitemid 30346438)
15. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-494. doi:10.2165/023210-2015060-05 PubMed (Pubitemid 32601905)
16. Welner M. Antipsychotic drugs and interactions: implications for criminal and civil litigation. In: Mozayani A, Raymon LP, eds. Handbook of Drug Interactions: A Clinical and Forensic Guide. Totowa, NJ: Humana Press; 2004:187-218. doi:10.107/978-1-6179-2-9-7
17. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi:10.2165/1318070-0-0 PubMed
18. Allen MH, Debanné M, Lazignac C, et al. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2011;168(4):395-399. doi:10.176/api.ajp.2010.1040569 PubMed